Log in | Register
Yukiyasu Okamura MD, Teiichi Sugiura MD, Takaaki Ito MD, Yusuke Yamamoto MD, Ryo Ashida MD, Katsuhisa Ohgi MD, Katsuhiko Uesaka MD Hepatobiliary Tumors Volume 26, Issue 13 / December , 2019
View full article HTML | View full article PDF | Download Citation
Hepatitis C virus (HCV) infection is a major cause of hepatocellular carcinoma (HCC). Achieving a sustained virological response (SVR) is associated with a reduced risk of recurrence. The recent introduction of direct acting antivirals (DAAs) has resulted in SVR rates of nearly 100% in treated patients. The purpose of the present study was to clarify the outcomes in patients who underwent antiviral therapy and patients without antiviral therapy.
This retrospective study included 220 patients with primary HCV-related HCC who underwent hepatectomy. An SVR was defined as a serum HCV-RNA titer below the detection sensitivity limit at 6 months after the termination of antiviral therapy. Postoperative antiviral therapy was introduced after confirming that there was no early recurrence.
Eighty-eight patients received antiviral therapy. Among these, 58 patients (66%) obtained an SVR. With the exception of one patient, all patients who received DAAs obtained an SVR. The overall survival rate of the pre-operative SVR group was significantly better than that of the preoperative untreated group (P = 0.045). Moreover, there was no recurrence at 3 years after surgery in the pre-operative SVR group. The achievement of an SVR was an independent predictor of overall survival [hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.59–0.94, P = 0.011] and recurrence (HR 0.61, 95% CI 0.40–0.94, P = 0.024).
Obtaining an SVR either before or after surgery was associated with the suppression of HCC recurrence after hepatectomy in patients with primary HCV-related HCC.
Go to Issue Contents
Add this article to your Personal Archive
ANNALS ON SOCIAL MEDIA
@AnnSurgOncol
Join the conversation!
Follow the journal on Twitter and Facebook.
Help to expand the reach of the journal to support the research and practice needs of surgical oncologists and their patients.